Top Back to top

EBMT and EHA joint meeting on CAR T cells, first of its kind in Europe

by

The EBMT and EHA will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatments in Europe provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment.

Patients, physicians, nurses, hospitals and the whole health care system need to learn how to select the right patients, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T Cell Therapy.

Christian Chabannon, Chair, EBMT Cellular Therapy & Immunobiology Working Party and EBMT Scientific Council Vice-Chair, explains: "The EBMT and EHA unite in designing this first-ever European Meeting which represents an amazing educational opportunity for healthcare professionals to get practical information to safely administer CAR-T Cells to a growing number of patients, both in Europe and worldwide."  

Hermann Einsele, Chair of the EHA Scientific Working Group on Immune Therapies for Hematologic Disorders adds: “Experts with various backgrounds and expertise will share their knowledge about CAR-T Cell Therapy and provide an overview of their current and future applications in cancer treatment, and how this translates in healthcare organizations.”

In addition, the program will include a comprehensive outlook on the current research efforts to increase the efficacy of CAR T Cell Therapy, with inputs from basic researchers as well as debates involving representatives from industry.

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org